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Editorial: Has C-Peptide Come of Age?
n this issue, a Consensus Statement on proinsulin C-
peptide is published summarizing the deliberations
of an international group of investigators, who met
in Detroit in October 2000. This was preceded by
the 3 rd International Motor City Symposium, the theme of
which was concerned with the clinical and biological
effects of C-peptide. The abstracts of the presentations at
the Symposium are also published in this issue of the
International Journal of Experimental Diabetes Research.
There is no doubt that the understanding of the actions
of C-peptide has come a long way since its original dis-
covery in the late 1960s. Ill A biological effect of C-peptide
was suspected at the time. It was hypothesized that C-pep-
tide would have an insulin-like glucose lowering effect.
However, several studies failed to demonstrate such an
effect and it was concluded that the only role played by C-
peptide was in the stereometric formation of insulin and
that it lacked further biological activities.
In the early 1990s, the interest in C-peptide was revi-
talized by Dr. John Wahren and his group at the
Karolinska Institute in Stockholm.121 In short time C-pep-
tide replacement studies in type diabetic patients demon-
strated beneficial effects on incipient nephropathy with
partial reversal of glomerular filtration rate and albumin
secretion. Beneficial effects were also demonstrated in
type patients with autonomic and sensory neuropathies.
These findings were paralleled by effects on skin and mus-
cle blood flow. These encouraging data energized the
search for potential mechanisms, which followed with the
demonstration of corrective effects on neural and renal
tubular Na//K+-ATPase and microvascular nitric oxide.
These findings appeared, at least in part, to explain the
clinical effects. A further milestone in the C-peptide saga
was the demonstration of its specific binding to cell mem-
branesI31 by Riegler and collaborators at the Karolinska
Institute. These findings strongly suggest a receptor-medi-
ated mechanism for C-peptide’s action. Studies addressing
the characterization of a specific C-peptide receptor are
ongoing at the Karolinska Institute. Simultaneous studies at
the Wayne State University/Morris Hood Diabetes Center
in Detroit suggested an alternative and/or adjunct mecha-
nism for C-peptide. Grunberger and collaborators I41
demonstrated activation of the insulin signaling pathway
by C-peptide alone and with additive effects when incubat-
ed together with insulin. These results were supported by
the finding that C-peptide autophosphorylates the insulin
receptor. Since C-peptide does not compete with insulin at
the receptor level, these findings may suggest a different lig-
and site for C-peptide. The receptor issue, particularly that
of a specific C-peptide receptor, is not settled and remains
one of the key issues to be firmly established, as stated in
the recommendations by the Consensus Statement.
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The enormous potential benefit of C-peptide in clinical
medicine undoubtedly lies in its probable effects in pre-
venting and ameliorating the chronic complications in
type diabetes, which account for the high morbidity and
mortality in this patient group. Long-term experimental
studies have demonstrated significant preventive and
interventional effects on diabetic neuropathylSl, which is
more severely expressed in type as compared to type II
diabetes. Another complication that is being increasingly
recognized clinically is a duration-dependent cognitive
deficit in type diabetic patients which is unrelated to
hypoglycemic episodes. There are experimental data from
the Detroit Center demonstrating a duration-dependent
programmed neuronal cell death in brain areas associated
with cognitive function and encouraging results showing
a significant protective effect following C-peptide replace-
ment on type diabetic rats.
In summary, both clinical and experimental data to
date are promising and further explorations of the biolog-
ical effects of this small peptide should be encouraged as
outlined by the Consensus Group. In lieu of any effective
treatment for most of the devastating chronic complica-
tions in type diabetes, C-peptide holds great promise as
an effective, inexpensive and simple therapy and, unlike
some of the evolving alternatives, is not likely to cause
adverse clinical effects.
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